CAJ | 학술논문

目的：评价替比夫定治疗慢性乙型肝炎患者的疗效及安全性。方法：检索替比夫定和拉米夫定治疗慢性乙型肝炎随机对照研究文献,对治疗效果、安全性等进行Meta分析。结果：替比夫定在生化反应、病毒学应答、降低HBeAg滴度、病毒学突破以及耐药发生率等方面优于拉米夫定,但在HBeAg和HBsAg转阴率上二者差异无统计学意义。随着疗程延长,替比夫定在HBeAg转阴率上高于拉米夫定,但不良反应和肌酸激酶升高的机会也随之增加。结论：替比夫定比拉米夫定具有更强的抑制乙肝病毒复制的作用,须重视不良反应。
목적：평개체비부정치료만성을형간염환자적료효급안전성。방법：검색체비부정화랍미부정치료만성을형간염수궤대조연구문헌,대치료효과、안전성등진행Meta분석。결과：체비부정재생화반응、병독학응답、강저HBeAg적도、병독학돌파이급내약발생솔등방면우우랍미부정,단재HBeAg화HBsAg전음솔상이자차이무통계학의의。수착료정연장,체비부정재HBeAg전음솔상고우랍미부정,단불량반응화기산격매승고적궤회야수지증가。결론：체비부정비랍미부정구유경강적억제을간병독복제적작용,수중시불량반응。
To evaluate the efficacy and safety of Telbivudine（LdT） and Lamivudine（LAM） in the treatment of chronic hepatitis B by meta-analysis,we have studied the relevant documents and materials.At the end of one-year treatment,LdT was better than LAM at the biochemical response,virological response,HBeAg loss,therapeutic response,while less than at the viral breakthrough and viral resistance,but there was no significant difference in the HBeAg seroconversion and HBsAg response.LdT was better than LAM at the HBeAg seroconversion with prolonged treatment.LdT was superior in inhibiting HBV replication and preventing drug resistance as compared to LAM for CHB patients.But LdT might cause more adverse reactions could can lead to more CK elevation.It is thus recommended that the LdT could be used as an option for patients but adverse reaction would be monitored.